Antiplatelet treatment restores BBB function in EcoHIV-infected mice.

<p>Plasma concentrations of PF4 and sCD40L in EcoHIV infected mice were determined via ELISA following the treatment with either saline or eptifibatide (10 μg per mouse). As indicated, <b>(A)</b> PF4 (n = 6/group) and <b>(B)</b> sCD40L (n = 6/group) levels were found to be lower in eptifibatide-treated, infected mice compared to infected mice treated with saline. (<b>C</b>) Eptifibatide treatment of EcoHIV-infected mice (n = 6/group) increases the bleeding time. (<b>D</b>) Flow cytometry analysis of activated platelets (CD61<sup>+</sup> CD62P<sup>+)</sup> after one mpi with EcoHIV shows that mice receiving eptifibatide have significantly lower percentage of CD62P<sup>+</sup> platelets than saline-treated control mice (n = 6/group). (<b>E</b>) Sodium fluorescein (NaF) exclusion assay revealed that eptifibatide treatment, with i.p. injections every 3 days over the course of 7 days, prevented EcoHIV-induced loss of BBB permeability one mpi (n = 6/group). <b>(F)</b> At two mpi CD62P<sup>+</sup> expression rebounded in infected mice when eptifibatide treatment was ceased (n = 6/group).</p>